Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Cash & Current Investments of $170.4 million for Q1 2026, up 82.84% year-over-year from $93.2 million in Q1 2025, and down 4.7% quarter-over-quarter from $178.8 million in Q4 2025.
Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Cash & Current Investments for 7 consecutive years, with $170.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments rose 82.84% year-over-year to $170.4 million; the TTM figure through Mar 2026 stood at $170.4 million (up 82.84% YoY), while the FY2025 annual figure was $178.8 million, up 83.27% from the prior year.
- Cash & Current Investments eased to $170.4 million in Q1 2026 per IKT's latest filing, from $178.8 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $178.8 million in Q4 2025 and bottomed at $3.2 million in Q3 2024.
- Historically, Cash & Current Investments has averaged $54.2 million across 5 years, with a median of $26.5 million in 2022.
- Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 80.73% — and 2025, when it jumped 2283.81%.
- Inhibikase Therapeutics' Cash & Current Investments stood at $23.1 million in 2022, then tumbled by 42.51% to $13.3 million in 2023, then jumped by 636.06% to $97.5 million in 2024, then surged by 83.27% to $178.8 million in 2025, then decreased by 4.7% to $170.4 million in 2026.
- Business Quant data shows IKT's Cash & Current Investments at $170.4 million in Q1 2026, $178.8 million in Q4 2025, and $77.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 159.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 159.02 Mn |
| Mar 31, 2026 | 170.37 Mn |
| Dec 31, 2025 | 178.76 Mn |
| Sep 30, 2025 | 77.32 Mn |
| Jun 30, 2025 | 87.67 Mn |
| Mar 31, 2025 | 93.18 Mn |
| Dec 31, 2024 | 97.54 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 7.94 Mn |
| Mar 31, 2024 | 9.75 Mn |
| Dec 31, 2023 | 13.25 Mn |
| Sep 30, 2023 | 16.83 Mn |
| Jun 30, 2023 | 20.94 Mn |
| Mar 31, 2023 | 25.72 Mn |
| Dec 31, 2022 | 23.05 Mn |
| Sep 30, 2022 | 26.53 Mn |
| Jun 30, 2022 | 32.21 Mn |
| Mar 31, 2022 | 36.61 Mn |
| Dec 31, 2021 | 40.75 Mn |
| Sep 30, 2021 | 44.85 Mn |